These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22711609)

  • 1. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.
    Harris RJ; Cloughesy TF; Pope WB; Nghiemphu PL; Lai A; Zaw T; Czernin J; Phelps ME; Chen W; Ellingson BM
    Neuro Oncol; 2012 Aug; 14(8):1079-89. PubMed ID: 22711609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.
    Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Grogan T; Elashoff D; Geist C; Silverman DH; Phelps ME; Chen W
    Clin Cancer Res; 2014 Jul; 20(13):3550-9. PubMed ID: 24687922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
    Wardak M; Schiepers C; Cloughesy TF; Dahlbom M; Phelps ME; Huang SC
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1199-209. PubMed ID: 24604590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
    Chen W; Delaloye S; Silverman DH; Geist C; Czernin J; Sayre J; Satyamurthy N; Pope W; Lai A; Phelps ME; Cloughesy T
    J Clin Oncol; 2007 Oct; 25(30):4714-21. PubMed ID: 17947718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
    Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
    Colavolpe C; Chinot O; Metellus P; Mancini J; Barrie M; Bequet-Boucard C; Tabouret E; Mundler O; Figarella-Branger D; Guedj E
    Neuro Oncol; 2012 May; 14(5):649-57. PubMed ID: 22379188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.
    Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Geist C; Dahlbom M; Silverman DH; Satyamurthy N; Phelps ME; Chen W
    J Nucl Med; 2012 Jan; 53(1):29-36. PubMed ID: 22159180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
    Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
    J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and grading accuracy of
    Xiao J; Jin Y; Nie J; Chen F; Ma X
    BMC Cancer; 2019 Aug; 19(1):767. PubMed ID: 31382920
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Patel CB; Fazzari E; Chakhoyan A; Yao J; Raymond C; Nguyen H; Manoukian J; Nguyen N; Pope W; Cloughesy TF; Nghiemphu PL; Czernin J; Lai A; Ellingson BM
    J Neurooncol; 2018 Sep; 139(2):399-409. PubMed ID: 29679199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identify glioma recurrence and treatment effects with triple-tracer PET/CT.
    Li C; Yi C; Chen Y; Xi S; Guo C; Yang Q; Wang J; Sai K; Zhang J; Ke C; Chen F; Lv Y; Zhang X; Chen Z
    BMC Med Imaging; 2021 May; 21(1):92. PubMed ID: 34059015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiating high-grade glioma progression from treatment-related changes with dynamic [
    Rozenblum L; Zaragori T; Tran S; Morales-Martinez A; Taillandier L; Blonski M; Rech F; Galanaud D; Kas A; Verger A
    Eur Radiol; 2023 Apr; 33(4):2548-2560. PubMed ID: 36367578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
    J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
    George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
    AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.
    Chiba Y; Kinoshita M; Okita Y; Tsuboi A; Isohashi K; Kagawa N; Fujimoto Y; Oji Y; Oka Y; Shimosegawa E; Morita S; Hatazawa J; Sugiyama H; Hashimoto N; Yoshimine T
    J Neurosurg; 2012 Apr; 116(4):835-42. PubMed ID: 22242671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas.
    Karavaeva E; Harris RJ; Leu K; Shabihkhani M; Yong WH; Pope WB; Lai A; Nghiemphu PL; Liau LM; Chen W; Czernin J; Cloughesy TF; Ellingson BM
    Mol Imaging Biol; 2015 Jun; 17(3):434-42. PubMed ID: 25465392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rate of change in maximum
    Oughourlian TC; Yao J; Schlossman J; Raymond C; Ji M; Tatekawa H; Salamon N; Pope WB; Czernin J; Nghiemphu PL; Lai A; Cloughesy TF; Ellingson BM
    J Neurooncol; 2020 Mar; 147(1):135-145. PubMed ID: 31981013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
    Yamaguchi S; Hirata K; Toyonaga T; Kobayashi K; Ishi Y; Motegi H; Kobayashi H; Shiga T; Tamaki N; Terasaka S; Houkin K
    PLoS One; 2016; 11(12):e0167917. PubMed ID: 27936194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.